X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2022/07/18/2481331/20739/en/Ultragenyx-and-GeneTx-Provide-Program-Update-on-GTX-102-for-Angelman-Syndrome-Including-Promising-Interim-Data-from-Phase-1-2-Study.html
https://www.streetinsider.com/Corporate+News/Ultragenyx+Pharma+%28RARE%29+and+GeneTx+Issues+Update+on+Phase+12+Clinical+Study+of+GTX-102/19422427.html
https://endpts.com/after-pumping-the-brakes-on-their-angelman-syndrome-study-ultragenyx-and-genetx-are-back-in-the-race/
https://www.clinicaltrialsarena.com/news/genetx-ultragenyx-angelman-syndrome-trial/
https://www.globenewswire.com/news-release/2021/05/19/2232478/20739/en/GeneTx-and-Ultragenyx-Receive-Clearance-from-Health-Canada-to-Begin-Clinical-Study-of-GTX-102-in-Canada-for-the-Treatment-of-Angelman-Syndrome.html
https://www.sciencemag.org/news/2020/11/gene-therapy-autism-linked-condition-weakened-legs-robbing-two-people-ability-walk
https://www.globenewswire.com/news-release/2020/10/26/2114609/0/en/GeneTx-and-Ultragenyx-Announce-Positive-Interim-Phase-1-2-Data-on-Investigational-GTX-102-Demonstrating-Improvement-in-Patients-with-Angelman-Syndrome.html
https://www.globenewswire.com/news-release/2020/05/04/2026747/0/en/GeneTx-and-Ultragenyx-Announce-GTX-102-Granted-Fast-Track-Designation-by-U-S-FDA-for-Treatment-of-Angelman-Syndrome.html
Market Place
Share 
